SVRA DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Savara Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action - SVRANovember 05, 2025 9:33 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024 and May 23, 2025, both dates inclusive ...

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Period”), of the important November 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased Savara securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO N ...

ATLANTA, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC reminds investors of the deadline to seek to be appointed lead plaintiff in the following class action lawsuits: Savara Inc. (SVRA) The shareholder class action lawsuit filed against Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material facts regarding Savara’s biologics license application for MOLBREEVI between March 7, 2024 and May 2 ...

NEW YORK, Nov. 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Period”), of the important November 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased Savara securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO N ...

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Period”), of the important November 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased Savara securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO N ...

Oct 30, 2025 2:56 PM Eastern Daylight Time SVRA Deadline: Rosen Law Firm Urges Savara Inc. (NASDAQ: SVRA) Stockholders to Contact the Firm for Information About Their Rights Share NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Savara Inc. (NASDAQ: SVRA), between March 7, 2024 and May 23, 2025, both dates inclusive (the "Class Period†). Savara is a clinical- stage biopha ...

案件核心信息 - Rosen Law Firm提醒在2024年3月7日至2025年5月23日期间购买Savara Inc (NASDAQ: SVRA) 证券的投资者，首席原告截止日期为2025年11月7日 [1] - 投资者可能有权通过风险代理收费安排获得补偿，无需支付任何自付费用 [1] 诉讼指控细节 - 指控称被告作出了虚假和/或误导性陈述，未能披露MOLBREEVI生物制剂许可申请缺乏有关化学、制造和控制的足够信息 [4] - 因此美国FDA不太可能以当前形式批准MOLBREEVI BLA [4] - 上述情况使得Savara不太可能在其向投资者陈述的时间框架内完成MOLBREEVI BLA的提交 [4] - MOLBREEVI监管批准的延迟增加了Savara需要筹集额外资金的可能性 [4] 律所背景信息 - Rosen Law Firm专注于证券集体诉讼和股东衍生诉讼，在全球代表投资者 [3] - 该律所曾达成针对中国公司的史上最大证券集体诉讼和解，并在2017年因证券集体诉讼和解数量被ISS Securities Class Action Services排名第一 [3] - 自2013年以来，该律所每年排名前四，已为投资者追回数亿美元，仅在2019年就为投资者确保了超过4.38亿美元 [3]

事件概述 - 一家名为Bragar Eagel & Squire PC的律师事务所宣布，已代表在2024年3月7日至2025年5月23日期间购买Savara Inc (NASDAQ: SVRA) 证券的投资者，向美国宾夕法尼亚州东区地方法院提起集体诉讼 [8] - 投资者申请成为首席原告的截止日期为2025年11月7日 [8] 诉讼指控内容 - 指控方称，Savara公司在上述类别期间内未能向投资者披露关键信息 [8] - 具体指控包括：公司未能披露其MOLBREEVI生物制剂许可申请缺乏关于化学、制造和控制方面的足够信息 [8] - 指控称，由于上述缺陷，美国FDA不太可能以当前形式批准该申请 [8] - 指控还称，这使得Savara公司不太可能在其向投资者承诺的时间框架内完成MOLBREEVI BLA的提交 [8] - 据称，MOLBREEVI监管批准的延迟增加了公司需要筹集更多资金的可能性 [8] 股价影响事件 - 2025年5月27日，Savara公司发布新闻稿，宣布其收到了FDA针对MOLBREEVI BLA的拒绝提交信件 [8] - 新闻稿披露，FDA经初步审查后认定，该申请不够完整，无法进行实质性审查，并要求提供更多与化学、制造和控制相关的数据 [8] - 此消息导致Savara公司股价下跌0.90美元/股，跌幅达31.69%，于2025年5月27日收于1.94美元/股 [8] 相关公司背景 - Savara Inc是一家上市公司，股票代码为SVRA [8] - 提起集体诉讼的Bragar Eagel & Squire PC是一家在全国范围内得到认可的律师事务所，在纽约、加利福尼亚和南卡罗来纳设有办事处 [5]

公司法律事件 - 律师事务所Faruqi & Faruqi正在调查针对Savara Inc的潜在索赔 并提醒投资者关于2025年11月7日担任集体诉讼主要原告的申请截止日期 [4] - 诉讼指控公司及其高管违反了联邦证券法 内容包括其MOLBREEVI生物制品许可申请缺乏足够的化学、制造和控制信息 导致FDA不太可能批准该申请 [6] - 2025年5月27日 Savara宣布收到FDA针对MOLBREEVI的拒绝提交函 导致公司股价当日下跌0.90美元 跌幅达31.69% 收盘报1.94美元 [7] 公司产品与监管 - 针对MOLBREEVI的监管审批延迟增加了公司需要筹集额外资本的可能性 [6] - 公司此前向投资者表示的MOLBREEVI BLA提交时间表很可能无法完成 [6]

NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Period”), of the important November 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased Savara securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO N ...